01 The American Cancer Society's "Cancer Facts & Figures 2025" report provides projections for the United States. It estimates that in 2025, there will be over 2 million new cancer cases and more than 618,000 cancer deaths in the U.S. The WHO and other research bodies have made projections for the coming decades based on current trends. For example, some projections estimate that if current trends continue, the number of new cancer cases could rise to over 33 million and deaths to 18 million by 2050. The survival rates are currently the lowest due to improper healthcare infrastructure and a lack of awareness among people in these countries. As a result, cancer cachexia, characterized by systemic inflammation, a negative protein, energy balance, and an unintentional loss of lean body mass, is more common in cancer patients due to the high incidence of malignancies globally.
01 Increasing Prevalence of Cancer CachexiaAccording to the International Agency for Research on Cancer- Globocan 2020 report, 9,958,133 cancer-related deaths globally in 2020 out of 19,292,789 new cancer cases were identified. Global estimates put the number of cancer cases within five years at 50,550,287. Globally, 28,887,940 new cases of cancer are anticipated by 2040.Additionally, as per GLOBOCAN 2020, lung cancer cases accounted for 2,206771 new cancer cases diagnosed in 2020 globally, with 495,773 pancreatic, 604,100 esophageal, 1,414,259 prostate, and 1,148,515 colon cancers diagnosed in 2020 globally. As cachexia is highly prevalent in patients with the types of cancer mentioned above, there exists an increasing demand for cancer cachexia therapeutics over the coming years.Europe accounts for approximately 22.8% of global cancer cases, as per GLOBOCAN 2020. Moreover, cancer incidence is estimated to increase by 21.0% from 2020 to 2040. This rate is relatively high, considering Europe has only 9.0% of the global population. Similarly, a high cancer prevalence rate was observed in Asia, with 9,503,710 new cancer cases in 2020, accounting for 49.3% of global cancer cases. The number of cases is estimated to increase by 59.2% from 2020 to 2040.Moreover, Cancer Research UK suggests that the population suffering from cancer is expected to increase. As per the report, if recent trends in the incidence of significant cancers and population growth are consistent, it is predicted that there will be 27.5 million new cancer cases worldwide each year by 2040, an increase of 61.7% from 2018. New cancer cases are expected to be higher in males, with an approximate rise of 67.6%, compared to females, with an estimated increase of 55.3%. Thus, the high cancer incidence surges the demand for advanced therapeutic drugs, which drives the growth of the studied market.
02 Strong R&d and Product PipelineOwing to the high incidence of cancer cachexia cases among cancer patients globally, there has been an increasing focus on clinical studies to identify the characteristics of cancer cachexia across several different types of cancers in humans. Understanding the molecular mechanisms involved in muscle loss throughout the progression of cancer cachexia is an urgent issue to improve cancer outcomes. Thus, extensive R&D activities are in progress with a vast product pipeline.The University of Copenhagen, in partnership with the New Zealand University Hospital, began clinical research on the impact of medical cannabis on lean body mass (cachexia) in patients receiving chemotherapy that included oxaliplatin or paclitaxel in December 2020. Thus, there has been increasing interest and research activities in evaluating various parameters related to cancer cachexia disease condition and simultaneous product pipeline development by the major players, which is expected to boost the studied market growth over the forecast period significantly.
03 Stringent Regulatory RequirementsAs cancer cachexia occurs more often in terminally ill cancer patients, the drugs used to treat this disorder usually must adhere strictly to the standards followed by other cancer drugs. Stringent regulatory requirements mean that many countries have long timelines for approving pharmaceutical drugs, especially cancer-related ones. Countries have significant differences in the time required to approve cancer drugs per their prevailing national regulatory standards. For example, in the United States, the FDA must decide within 12 months on regular applications, and within six months, in the case of applications designated for priority review.In Europe, the CHMP must give its opinion within 210 days. This is followed by a decision-making phase that can take up to three months. Thus, patients generally gain access to promising drugs (like drugs for cancer cachexia) at different times. This severely limits the marketing ability of most large companies. As cancer cachexia drugs are administered to terminally ill patients, late approvals in countries mean that many patients lose out on potentially necessary medication that can be used to improve their quality of life.Due to the multifactorial character of cachexia, multimodal interventional trials, like the MENAC study, offer the best chance to connect response with a therapeutic intervention, according to the research article published in Annals of Palliative Medicine in 2019. Hence, meeting the endpoints, as per the requirements of regulatory bodies, has to be worked on for the successful acceptance of the study and subsequent drug approval. Thus, the issues mentioned above act as significant market restraints for the growth of the cancer cachexia market.
September 2025 Axcella Therapeutics expanded research activities around metabolic and muscle health applications, supporting the development of targeted approaches for conditions involving muscle loss and impaired energy metabolism, including oncology-related wasting disorders.
July 2025 Actimed Therapeutics advanced its lead investigational therapy S-pindolol benzoate (SLV-337) for cancer cachexia, progressing clinical development of treatments designed to address muscle wasting and functional decline associated with the condition.
June 2025 Helsinn Healthcare expanded its oncology supportive care portfolio through continued development and commercialization initiatives focused on improving quality of life for cancer patients, including management of cancer-related symptoms such as appetite loss and weight decline.
May 2025 Astellas Pharma expanded its oncology supportive care pipeline by advancing development programs targeting cancer cachexia and cancer-related metabolic disorders, strengthening its focus on therapies addressing unmet needs in patients with advanced cancer.